-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EypqNFgBCeolrl8EBJ/ys56KRpE8TR+QmSMPEPEihQWuYXemPPS+dpb0wNG6ziIH WnHu9MhDCMxYleV+j4i3rQ== 0001140361-08-028466.txt : 20081222 0001140361-08-028466.hdr.sgml : 20081222 20081222144243 ACCESSION NUMBER: 0001140361-08-028466 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20081216 FILED AS OF DATE: 20081222 DATE AS OF CHANGE: 20081222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CAMPBELL ANTHONY R CENTRAL INDEX KEY: 0001073308 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10352 FILM NUMBER: 081263505 BUSINESS ADDRESS: STREET 1: TC MANAGEMENT STREET 2: 237 PARK AVE STE 800 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2128083444 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: COLUMBIA LABORATORIES INC CENTRAL INDEX KEY: 0000821995 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 592758596 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 354 EISENHOWER PARKWAY CITY: LIVINGSTON STATE: NJ ZIP: 07039 BUSINESS PHONE: 9739943999 MAIL ADDRESS: STREET 1: 354 EISENHOWER PARKWAY CITY: LIVINGSTON STATE: NJ ZIP: 07039 3 1 doc1.xml FORM 3 X0203 3 2008-12-16 0 0000821995 COLUMBIA LABORATORIES INC CBRX 0001073308 CAMPBELL ANTHONY R KNOTT PARTNERS LP 485 UNDERHILL BOULEVARD SYOSSETT NY 11791 1 0 0 0 $0.01 par value common stock 111368 D $0.01 par value common stock 9125 I By custodian of Individual Retirement Account Series C Convertible Preferred Stock $0.01 par value common stock 0 I By custodian of Individual Retirement Account Includes award of 20,833 restricted Shares of Common Stock upon election to Board that vest at the 2009 Annual Meeting. Shares of Series C Convertible Preferred Stock are convertible into Shares of Common Stock at any time after June 17, 1999. The number of Shares of Common Stock issuable upon conversion of a Share of the Series C Convertible Preferred Stock will be such number as is equal to the quotient obtained by dividing the stated value of such share ($1,000) by the lower of: (i) $3.50, and (ii) 100% of the average of the closing prices of the Common Stock on the three trading days immediately preceding the receipt by the Company of a conversion notice. This report relates to 175 shares of Series C Convertible Preferred Stock. /s/ James A. Meer for Anthony R. Campbell 2008-12-22 EX-24.1 2 poa1.htm POWER OF ATTORNEY Unassociated Document
Exhibit 24.1
 
COLUMBIA
LABORATORIES, INC.
 
354 Eisenhower Pkwy
Livingston, NJ 07039
 
TEL: (973) 994-3999
FAX: (973) 994-3001
 
 
 
 


Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Attn: Filing Desk


Ladies and Gentlemen:

By means of this letter, I authorize Michael McGrane and James A. Meer, or either of them individually, to sign on my behalf all forms required under Section 16(a) of the Securities Exchange Act of 1934, as amended, relating to transactions involving the stock or derivative securities of Columbia Laboratories, Inc.  Either such individual is accordingly authorized to sign any Form 3, Form 4, Form 5, or amendment thereto, that I am required to file with the same effect as if I had signed it myself.

This authorization, signed this 16th day of December, 2008, shall remain in effect until revoked in writing by me. This authorization revokes all prior authorizations by me relating to the subject matter hereof.


Yours truly,


/S/Anthony R. Campbell
  
Anthony R. Campbell
  
Director
  

 
 -----END PRIVACY-ENHANCED MESSAGE-----